Quarterly ResultAug 7, 2026, 04:10 PM
OraSure Q2 Net Income $6.2M; Withdraws CT/NG Test Submission
AI Summary
OraSure Technologies reported a net income of $6.2 million for Q2 2026, a substantial improvement from a net loss of $(19.7) million in Q2 2025, primarily driven by a $22.6 million reduction in acquisition-related contingent consideration. This reduction followed the withdrawal of its 510(k) submission for the CT/NG rapid molecular self-test in July 2026. Despite the net income gain, net revenues for the quarter decreased by 1.9% to $30.6 million. The company also incurred $1.3 million in charges from a Q1 2026 workforce reduction.
Key Highlights
- Q2 2026 net income was $6.2 million, a significant improvement from $(19.7) million loss in Q2 2025.
- Basic EPS for Q2 2026 was $0.09, up from $(0.26) in the prior year period.
- Net revenues for Q2 2026 decreased 1.9% to $30.6 million from $31.2 million.
- Withdrew 510(k) submission for CT/NG rapid molecular self-test in July 2026.
- Acquisition-related contingent consideration liability reduced by $22.6 million due to submission withdrawal.
- Net cash used in operating activities improved to $(23.8) million for H1 2026.
- Q1 2026 workforce reduction incurred $1.3 million in charges for the six months.
- HIV product revenue was $14.2 million in Q2 2026, and Sample Management Solutions revenue was $9.9 million.
Price Impact
More from OSUR